Formulary Monographs [ARTESUNATE, 083008]
|
|
ARTESUNATE
|
|
|
|
|
|
ANTIMALARIALS
|
|
|
Malaria. Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
|
|
|
Gastrointestinal disturbances, pruritus and rash, dizziness, headache, tinnitus, neutropenia, elevated liver enzyme values, and ECG abnormalties including prolongation of the QT interval.
|
|
|
Oral: 4 mg/kg once daily , for 3 days. IM or IV: 2.4 mg/kg repeated after 12 and 24 hours and then once daily thereafter, transferring to an appropriate oral regimen after at least 24 hours.
|
|
|
|
|
|
Severe or complicated falciparum malaria is associated with a high risk of fatality, pregnancy loss, and complications. Due to efficacy, treatment with intravenous artesunate in any trimester of pregnancy is preferred;
|
|
|
|
|
|
|